Novo Nordisk overtakes LVMH as Europe's most valuable listed company

Novo Nordisk, the Danish maker of Ozempic and Wegovy, passed French luxury group LVMH on Friday, Sept. 1, 2023, to become Europe's most valuable listed company, ending LVMH's two-and-a-half-year run at the top ^[1].

As of Friday's close, Novo Nordisk had a market capitalization of about $424.7 billion, including unlisted stock, based on Refinitiv data and the company's own disclosures of its share count ^[1]. LVMH, listed in France, was valued at about $420.1 billion ^[1]. LVMH had held the No. 1 spot in Europe since February 2021, when it displaced consumer goods company Nestlé ^[1].

What drove the move

Novo's shares rose roughly 17% after Aug. 8, 2023, when the company said a large trial showed Wegovy (semaglutide) also produced a clear cardiovascular benefit ^[1]. According to Novo, the study data showed Wegovy cut the risk of a major cardiovascular event such as a stroke by 20% in people who were overweight or obese and had a history of heart disease — a bigger effect than analysts had expected ^[1].

Novo's share price has roughly tripled over the past three years, while LVMH's has doubled ^[1]. On Friday, Novo shares closed up 2.14% and LVMH shares fell 0.8% ^[1]. LVMH, which owns Louis Vuitton, Dior, Hennessy and Tiffany, has dropped 14.2% from its April record high, hurt by worries about China's slowing economy and property sector ^[1].

Analysts framed Novo's rise as a bet on the size of the obesity drug market. Sales of weight-loss drugs currently run around $6 billion a year, according to Barclays, but the market is expected to reach $100 billion in annual sales within a decade ^[1]. "The market share should be split relatively equally between Novo Nordisk and Eli Lilly, the two main companies behind obesity treatments," said Axelle Pinon of Carmignac's investment committee ^[1]. Reuters reported that Eli Lilly was expected to win a U.S. weight-loss approval later in 2023 for tirzepatide, sold for type 2 diabetes as Mounjaro ^[1].

Why it matters for patients

Stock prices are not medicine, but they are a rough gauge of how much money is flowing toward these drugs — and that affects supply, research and insurance fights.

The most direct patient issue in the Reuters report is cost and coverage. Wegovy carried a U.S. list price of $1,300 a month at the time ^[1]. Reuters noted that the cardiovascular result "may help persuade insurers and health authorities to cover the cost of Wegovy" for a wider range of patients ^[1]. Pinon put it in investor terms: "These results are de-risking the forward adoption curve for these drugs, justifying such a market move" ^[1]. In plain language, both investors and insurers were reacting to the same new evidence — that semaglutide may do more than lower weight and blood sugar.

The second point is competition. If the market really does split between Novo Nordisk and Eli Lilly, as the analyst quoted by Reuters expects, patients would eventually have more than one branded option in the same drug class ^[1]. What that does to prices, pharmacy stocking or prior-authorization rules is not addressed in the source and is not yet known.

A note on the numbers: some later accounts describe Novo's market value as passing $421 billion. Reuters, using Refinitiv data, put Novo at about $424.7 billion and LVMH at about $420.1 billion at Friday's close ^[1]. Market values change minute to minute, and Reuters described the overtaking as brief in its own headline ^[1].

What happens next

• Aug. 8, 2023: Novo announced topline cardiovascular results for Wegovy; full trial details had not been published as of the Reuters report ^[1].
• Later in 2023: Eli Lilly was expected to receive U.S. approval of tirzepatide for weight loss ^[1]. The Reuters story predates that decision.
• Ongoing: Analysts said Novo's rally would likely raise its weighting in the STOXX 600 index, potentially drawing more money from passive investors ^[1].

The Reuters report does not address U.S. shortages, compounded semaglutide, or whether the list price of Wegovy would change. Those questions remain open in this source.